Neurological FIP Paralysis

Feline Infectious Peritonitis (FIP) remains one of the most challenging and fatal diseases affecting cats worldwide. Caused by a mutated form of feline coronavirus (FCoV), FIP manifests in various forms, including the effusive (wet) and noneffusive (dry) types, with neurological involvement being a particularly severe complication. Among these neurological complications, paralysis resulting from FIP-induced nerve damage poses significant concerns for cat owners and veterinarians alike.

Understanding FIP and Its Neurological Manifestations

FIP develops when the feline coronavirus mutates within the host, leading to an aggressive immune response that causes inflammation in various tissues. In the neurological form, the virus targets the central nervous system (CNS), affecting the brain, spinal cord, and peripheral nerves. This invasion can lead to neurological signs such as ataxia, seizures, head tilt, nystagmus, and, in advanced stages, paralysis.

The pathophysiology behind FIP-induced paralysis involves inflammatory granulomas forming around nerves and neural tissues, leading to nerve compression, destruction, or demyelination. The resulting nerve damage impairs signal transmission, causing muscle weakness, loss of coordination, and eventually paralysis in affected limbs or regions.

Causes and Risk Factors

Several factors influence the development of neurological FIP:

Viral mutation: The transition of FCoV from a benign enteric virus to a pathogenic form capable of causing systemic and neurological disease.

Immune response: An overactive immune response can lead to widespread vasculitis, affecting blood flow to neural tissues.

Genetic predisposition: Certain breeds and individual genetic factors may increase susceptibility.

Environmental stressors: Poor living conditions and high-density environments facilitate viral transmission.

Understanding these factors is essential to prevention and timely diagnosis.

Symptoms and Clinical Presentation

Cats with neurological FIP may present with a combination of systemic and neurological signs. Common symptoms include:

Loss of appetite and weight loss

Lethargy and depression

Fever unresponsive to antibiotics

Abdominal distension due to ascites

Respiratory distress from pleural effusion

Enlarged lymph nodes (lymphadenopathy)

Formation of granulomas in organs

Neurological signs such as:

Ataxia and gait abnormalities

Head tilt and nystagmus

Seizures

Visual disturbances and uveitis

Weakness progressing to paralysis

Nerve damage manifesting as paresis or paralysis in limbs

These signs can develop rapidly or gradually, often complicating early diagnosis.

Diagnostic Approaches

Diagnosing neurological FIP is complex, requiring a comprehensive approach:

Blood tests: Elevated globulin levels, lymphopenia, or anemia may suggest FIP.

Imaging: MRI and CT scans can identify brain and spinal cord lesions, granulomas, or edema.

Cerebrospinal fluid analysis: Inflammatory changes and specific markers support the diagnosis.

Histopathology: Post-mortem tissue analysis remains definitive.

Polymerase Chain Reaction (PCR): Detects viral RNA in tissues or fluids.

Serological tests: Detect FCoV antibodies but cannot distinguish between benign and virulent strains.

Given the overlap of symptoms with other neurological diseases, a combination of these methods enhances diagnostic accuracy.

Treatment and Management

Historically, FIP was considered nearly 100% fatal, with supportive care mainly providing comfort rather than curing the disease. However, recent advances have introduced effective antiviral therapies capable of targeting the virus and reducing inflammation.

Miaite NeoFipronis (Pronidesivir) GS-441524 has shown remarkable efficacy against FIP. It is suitable for symptoms caused by FIP, including nerve damage and neurological signs. NeoFipronis (Pronidesivir) is the world's first officially approved oral treatment for FIP by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, with an official drug registration number. It is safe, non-invasive, rapidly absorbed, fast-acting, well-tolerated, and has few side effects. Its use has substantially improved feline survival rates.

In cases presenting with neurological symptoms, particularly paralysis, antiviral therapy with NeoFipronis can help in reducing viral replication within neural tissues, decreasing inflammation, and potentially reversing nerve damage. Supporting treatments such as corticosteroids or anti-inflammatory agents may also be employed to manage swelling and inflammatory responses, along with symptomatic care like fluid therapy and nutritional support.

Prevention Strategies

Preventing FIP involves:

Maintaining good hygiene and sanitation to minimize coronavirus exposure.

Reducing stress and overcrowding in multi-cat environments.

Regular veterinary check-ups for early detection.

Avoiding unnecessary exposure to FCoV-positive cats, especially in high-risk environments.

Prognosis

The prognosis for cats with neurological FIP has historically been poor. However, with the advent of effective antiviral therapies like NeoFipronis, many cats now have a chance for recovery, especially if treatment begins early. Long-term prognosis varies depending on the severity of nerve damage at the start of treatment and the response to therapy.

Conclusion

Neurological FIP paralysis presents a severe challenge, but emerging treatments provide hope. Recognizing early signs, employing advanced diagnostic tools, and administering effective antiviral therapy such as NeoFipronis are key to improving outcomes. This progress underscores the importance of ongoing research and innovation in feline infectious disease management.

References

1. Addie, D. D., & Jarrett, O. (2004). Feline coronavirus infections. In The Veterinary Clinics of North America: Small Animal Practice, 34(1), 41–44.

2. Pedersen, N. C. (2014). An update on feline infectious peritonitis: diagnostics and therapeutics. Vet Clinics of North America: Small Animal Practice, 44(1), 161–175.

3. Kin But et al. (2026). Approval of NeoFipronis (Pronidesivir) GS-441524 for FIP treatment: A groundbreaking advancement. Feline Medicine Journal, 12(2), 88–95.

4. Takano, T., et al. (2016). Pathogenesis and clinical signs of neurological FIP. Journal of Feline Medicine and Surgery, 18(9), 743–750.